Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline and Theravance begin new COPD drug trial

GlaxoSmithKline and Theravance begin new COPD drug trial

17th July 2014

GlaxoSmithKline and Theravance have allied to trial a new chronic obstructive pulmonary disease (COPD) drug in a global phase III study called Impact.

Involving approximately 10,000 patients, the study will assess whether the combination of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) delivered via the Ellipta inhaler can be a safe and effective treatment option.

The aim of the trial will be to see whether FF/UMEC/VI can reduce the annual rate of moderate and severe exacerbations compared with two approved once-daily COPD treatments, Relvar/Breo Ellipta and Anoro.

It represents the first pivotal phase III study to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist in the treatment of this disease.

Dave Allen, head of respiratory therapy research and development at GlaxoSmithKline, said: "The Impact study will be important in advancing our understanding of how the combination of FF/UMEC/VI could be used in this setting when compared to dual combination therapy options."

This comes after the companies received approval for the European launch of Anoro in May this year.ADNFCR-8000103-ID-801735904-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.